Poor Th1 response may be explained by T cell inhibition, either by T-cell tolerance to tumor antigens (PD-1 and CTLA-4 pathways) or increased pro-apoptosis of CD4+ T cells (Fas pathway). This evidence concerns the gene CD4 and neoplasm.